| HIV Infections
Dovato vs Reyataz
Side-by-side clinical, coverage, and cost comparison for hiv infections.Deep comparison between: Dovato vs Reyataz with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsReyataz has a higher rate of injection site reactions vs Dovato based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Reyataz but not Dovato, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Dovato
Reyataz
At A Glance
Oral
Once daily
INSTI/NRTI combination
Oral
Once daily
HIV-1 protease inhibitor
Indications
- HIV Infections
- HIV Infections
Dosing
HIV Infections One tablet (dolutegravir 50 mg/lamivudine 300 mg) orally once daily with or without food; when coadministered with carbamazepine or rifampin, take one additional dolutegravir 50-mg tablet approximately 12 hours after the DOVATO dose.
HIV Infections (treatment-naive adults) 300 mg once daily with ritonavir 100 mg once daily with food, or 400 mg once daily with food if unable to tolerate ritonavir
HIV Infections (treatment-experienced adults) 300 mg once daily with ritonavir 100 mg once daily with food; 400 mg once daily with ritonavir 100 mg once daily if taken with both tenofovir DF and H2-receptor antagonist
HIV Infections (pediatric patients 6 to less than 18 years, 15 to less than 35 kg) 200 mg once daily with ritonavir 100 mg once daily with food
HIV Infections (pediatric patients at least 35 kg) 300 mg once daily with ritonavir 100 mg once daily with food
HIV Infections (pediatric patients at least 3 months, 5 to less than 15 kg) 200 mg oral powder once daily with ritonavir 80 mg once daily with food
HIV Infections (pregnant patients) 300 mg once daily with ritonavir 100 mg once daily with food; 400 mg once daily with ritonavir 100 mg once daily during second or third trimester when coadministered with either H2-receptor antagonist or tenofovir DF
Contraindications
- Prior hypersensitivity reaction to dolutegravir or lamivudine
- Concurrent use of dofetilide due to risk of increased dofetilide plasma concentrations and serious or life-threatening events
- Previously demonstrated clinically significant hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, toxic skin eruptions) to any component
- Coadministration with drugs highly dependent on CYP3A or UGT1A1 for clearance where elevated plasma concentrations are associated with serious or life-threatening events (alfuzosin, cisapride, pimozide, orally administered midazolam, triazolam, ergot derivatives, lovastatin, simvastatin, lomitapide, sildenafil for pulmonary arterial hypertension, indinavir, irinotecan, lurasidone when boosted with ritonavir, apalutamide, encorafenib, ivosidenib, elbasvir/grazoprevir, glecaprevir/pibrentasvir)
- Coadministration with strong CYP3A inducers (rifampin, St. John's wort, carbamazepine, phenobarbital, phenytoin, nevirapine)
Adverse Reactions
Most common (>=2%) Headache, nausea, diarrhea, insomnia, fatigue, anxiety, dizziness
Serious Hypersensitivity reactions, hepatotoxicity, lactic acidosis and severe hepatomegaly with steatosis, immune reconstitution syndrome
Postmarketing Body fat redistribution, hyperglycemia, weakness, severe anemia, lactic acidosis and hepatic steatosis, pancreatitis, posttreatment exacerbations of HBV, acute liver failure, anaphylaxis, urticaria, weight gain, arthralgia, CPK elevation, muscle weakness, myalgia, rhabdomyolysis, paresthesia, peripheral neuropathy, alopecia
Most common (>=2%) Nausea, jaundice/scleral icterus, rash, headache, insomnia, dizziness, vomiting, abdominal pain, diarrhea, fever, myalgia, depression, peripheral neurologic symptoms
Serious Cardiac conduction abnormalities (PR interval prolongation, second-degree AV block, third-degree AV block), chronic kidney disease, nephrolithiasis, cholelithiasis
Postmarketing Edema, QTc prolongation, left bundle branch block, pancreatitis, hepatic function abnormalities, cholecystitis, cholestasis, diabetes mellitus, hyperglycemia, arthralgia, interstitial nephritis, granulomatous interstitial nephritis, alopecia, maculopapular rash, pruritus, angioedema
Pharmacology
DOVATO is a fixed-dose combination of dolutegravir, an HIV-1 integrase strand transfer inhibitor (INSTI) that blocks retroviral DNA integration by binding to the integrase active site, and lamivudine, a nucleoside analogue reverse transcriptase inhibitor (NRTI) that inhibits reverse transcriptase via DNA chain termination after incorporation of the nucleotide analogue.
Atazanavir is an azapeptide HIV-1 protease inhibitor that selectively inhibits virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1-infected cells, preventing formation of mature virions.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Dovato
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
Reyataz
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Dovato
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (7/8)
Reyataz
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Dovato
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Reyataz
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
DovatoView full Dovato profile
ReyatazView full Reyataz profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.